3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 2
2
Phase 3
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
3
Ureteral Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urethral Neoplasms
1
Renal Insufficiency
1
Recurrence
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Neoplasms
1
Kidney Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms, Male
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
vinflunine
×
Clear all
NCT01529411
2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2
Completed
86 enrolled
NCT01599013
2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2
Completed
69 enrolled